What Wegovy does to your heart: the evidence so far

What the SELECT trial actually found, and why it changed Wegovy's licence

The SELECT cardiovascular outcomes trial enrolled 17,604 adults aged 45 and over who had established cardiovascular disease, a BMI of 27 or above, and no history of diabetes. Participants received either semaglutide 2.4mg weekly or placebo, alongside standard care, for an average of around 34 months. The primary endpoint (a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke) was reduced by 20% in the semaglutide group. That is a statistically significant result with a number needed to treat that impressed regulators on both sides of the Atlantic.

On the strength of this data, the MHRA granted Wegovy a second UK authorisation: not just weight management, but the reduction of major cardiovascular event risk in adults with obesity or overweight and established cardiovascular disease. That dual licence is clinically meaningful. It means a prescriber treating someone for heart health as well as weight has a genuine evidence base to work from, rather than extrapolating from surrogate markers.

The mechanism is not fully resolved. Weight loss itself reduces cardiovascular strain, but researchers observed cardiovascular benefit in the SELECT trial that appeared partly independent of how much weight participants lost. Whether the GLP-1 receptor agonism is acting directly on cardiac tissue, on inflammation, or through some other pathway remains an active area of research. The honest answer is: the benefit is real, the full explanation is not yet settled.

The heart rate question: a modest rise, regularly monitored

One consistent finding across GLP-1 trials is a small increase in resting heart rate, typically in the range of two to four beats per minute on average. For most people this is clinically unremarkable. For someone with a pre-existing arrhythmia or heart failure, it is the kind of detail a prescriber needs to weigh carefully before starting treatment.

The NHS semaglutide medicines page lists heart rate changes among the side effects to be aware of, alongside the more common gastrointestinal symptoms. If you notice a noticeably faster or irregular heartbeat during treatment, that is worth raising with your prescriber or GP rather than waiting for a scheduled review. It is also the kind of thing the MHRA continues to monitor through the Yellow Card scheme, which accepts reports from patients directly, not just clinicians.

The wider picture on heart failure is incomplete. SELECT did not specifically enrol people with existing heart failure as a primary group, so the evidence base for that population is thinner. Research is ongoing. If heart failure is part of your history, a prescriber will factor that in, it does not automatically exclude you, but it changes the clinical conversation.

Who the cardiovascular indication applies to, and the suitability assessment

The cardiovascular licence for Wegovy covers adults with a BMI of 27 or above who have established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease, for example). It does not extend to people who simply want to reduce a future cardiovascular risk with no prior event, that is a different clinical category, and the evidence for it is less mature.

If you are in the SELECT-eligible group, treatment through a regulated private service remains an option while NHS pathways develop. The cost context for private treatment is worth understanding clearly; you can read a factual breakdown on what Wegovy costs in the UK and what those prices typically include. What matters at least as much as price is that you are receiving a prescription from a clinician who has seen your full picture, not a form assessed by software.

For a broader overview of how semaglutide works and what it is licensed for, the Wegovy treatment page covers the key facts. And if your interest is specifically in Wegovy's effects on organs beyond the heart, the research on what Wegovy does to the liver is increasingly compelling, particularly for people with fatty liver disease alongside cardiovascular risk.

Practical points if you have a heart condition and are considering treatment

Semaglutide interacts with the body's broader metabolic and autonomic systems, so starting treatment when you have cardiac history is not simply a matter of meeting a BMI threshold. A prescriber needs to know your current cardiac medications, any implanted devices, recent hospital admissions, and whether your condition is stable. Anticoagulants, antiarrhythmics and some antihypertensives all appear on a list of things to consider alongside GLP-1 medicines; your prescriber reviews this before approving treatment, not as a tick-box exercise but as a genuine clinical assessment. Those considering semaglutide for cardiovascular reasons may also find it useful to read about how semaglutide affects the liver, given how closely metabolic and cardiac risk factors tend to overlap.

Timing of appointments matters in practice too. Our prescribers review consultations the same working day they arrive, if something comes up over the bank holiday weekend or after a busy Friday, a Monday-morning submission still reaches a clinician that day. There is no bot in between. If you have questions about whether your cardiac history makes you a suitable candidate, the free consultation is the right place to raise them in full.

Pregnancy, breastfeeding, and trying to conceive are situations where Wegovy is not recommended regardless of cardiovascular status; anyone in those circumstances should speak with their GP before any weight-management medicine is considered. For more on that specific question, you can read about how semaglutide affects pregnancy and what the current guidance says, which is covered in detail separately.

If you would like a prescriber to review your eligibility, check your eligibility through a free consultation, there is no obligation, and the review happens the same day.